Baras B, Benoit M A, Dupré L, Poulain-Godefroy O, Schacht A M, Capron A, Gillard J, Riveau G
Laboratoire de Pharmacie Galénique, Industrielle et Officinale, Ecole de Pharmacie, Université Catholique de Louvain, B-1200 Brussels, Belgium.
Infect Immun. 1999 May;67(5):2643-8. doi: 10.1128/IAI.67.5.2643-2648.1999.
The purpose of this work was to assess the immunogenicity of a single nasal or oral administration of recombinant 28-kDa glutathione S-transferase of Schistosoma mansoni (rSm28GST) entrapped by poly(lactide-co-glycolide) (PLG)- or polycaprolactone (PCL)-biodegradable microparticles. Whatever the polymer and the route of administration used, the equivalent of 100 microg of entrapped rSm28GST induced a long-lasting and stable antigen-specific serum antibody response, with a peak at 9 to 10 weeks following immunization. Isotype profiles were comparable, with immunoglobulin G1 being the predominant isotype produced. The abilities of specific antisera to neutralize the rSm28GST enzymatic activity have been used as criteria of immune response quality. Pooled 10-week sera from mice receiving PLG microparticles by the nasal or oral route neutralized the rSm28GST enzymatic activity, whereas sera of mice receiving either PCL microparticles, free rSm28GST, or empty microparticles inefficiently neutralized this enzymatic activity. Finally, this study shows that a single administration of these microparticles could provide distinct and timely release pulses of microencapsulated antigen, which might greatly facilitate future vaccine development.
本研究旨在评估经鼻或口服给予包裹于聚（丙交酯-乙交酯）（PLG）或聚己内酯（PCL）可生物降解微粒中的曼氏血吸虫重组28-kDa谷胱甘肽S-转移酶（rSm28GST）的免疫原性。无论使用何种聚合物及给药途径，相当于100μg包封的rSm28GST均诱导出持久且稳定的抗原特异性血清抗体反应，免疫后9至10周达到峰值。同种型谱具有可比性，其中免疫球蛋白G1是产生的主要同种型。特异性抗血清中和rSm28GST酶活性的能力已被用作免疫反应质量的标准。经鼻或口服途径接受PLG微粒的小鼠的10周合并血清可中和rSm28GST酶活性，而接受PCL微粒、游离rSm28GST或空微粒的小鼠血清对该酶活性的中和效率较低。最后，本研究表明单次给予这些微粒可提供微囊化抗原的独特且适时的释放脉冲，这可能极大地促进未来疫苗的开发。
